MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
70.67
-10.00
-12.40%
After Hours: 71.78 +1.11 +1.57% 19:44 09/15 EDT
OPEN
82.89
PREV CLOSE
80.67
HIGH
83.55
LOW
70.61
VOLUME
4.37M
TURNOVER
--
52 WEEK HIGH
95.49
52 WEEK LOW
28.12
MARKET CAP
9.98B
P/E (TTM)
-31.5449
1D
5D
1M
3M
1Y
5Y
1D
Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA
TipRanks · 15h ago
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Barchart · 20h ago
Weekly Report: what happened at ARWR last week (0907-0911)?
Weekly Report · 1d ago
Goldman rebalances its long duration stock basket
Seeking Alpha · 2d ago
How Investors May Respond To Arrowhead Stock Phase 3 Trial Results
Simply Wall St · 6d ago
Citi adds ‘upside 30-day catalyst watch’ on Arrowhead
TipRanks · 6d ago
Arrowhead Pharmaceuticals Price Target Announced at $108.00/Share by Citigroup
Dow Jones · 09/08 16:14
Arrowhead Pharmaceuticals Initiated at Buy by Citigroup
Dow Jones · 09/08 16:14
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.